The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583

Preclinical and phase 1 study results indicate that BI 1291583 is a reversible, highly potent and highly selective CatC inhibitor that markedly inhibits active NSP production in a dose-dependent manner, supporting phase 2 trials in bronchiectasis patients https://bit.ly/47PZ8E5.

• Chalmers, J. D.
• Badorrek, P.
• Diefenbach, C.
• Kögler, H.
• Sauter, W.
• Kreideweiss, S.
• Hohlfeld, J. M.